Abstract

BackgroundBladder cancer (BC) is a common urothelial malignancy, characterized by a high recurrence rate. The biology of bladder cancer is complex and needs to be deciphered. The latest evidence reveals the critical role of the non-coding RNAs, particularly microRNAs (miRNAs), as vital regulatory elements in cancer.MethodWe performed a miRNAs microarray using paired tissues (tumor and adjacent normal bladder tissue), followed by the validation with qRT-PCR of five selected transcripts. Additional next-generation sequencing investigation established the interconnection among the altered miRNAs and mutated genes. Based on the overlapping between TCGA data and data obtained in the study, we focused on the systematic identification of altered miRNAs and genes mutated involved in bladder cancer tumorigenesis and progression.ResultsBy overlapping the miRNAs expression data, the two patient cohorts, we identified 18 miRNAs downregulated and, 187 miRNAs upregulated. qRT-PCR validation was completed using a selected panel of two downregulated (miR-139-5p and miR-143-5p) and three up-regulated miRNAs (miR-141b, miR-200 s or miR-205). Altered miRNAs patterns are interrelated to bladder tumorigenesis, allowing them to be used for the development of novel diagnostic and prognostic biomarkers. Three EMT-related upregulated miRNAs have an essential role in the molecular mechanisms, specifically key processes underlying tumorigenesis, invasion and metastasis. Using the Ampliseq Cancer Panel kit and Ion Torrent PGM Next-Generation Sequencing an increased mutation rate for TP53, FGFR3, KDR, PIK3CA and ATM were observed, but the mutational status for only TP53 was correlated to the survival rate. The miRNAs pattern, along with the gene mutation pattern attained, can assist for better patient diagnosis.ConclusionThis study thereby incorporates miRNAs as critical players in bladder cancer prognosis, where their altered gene expression profiles have a critical biological function in relationship with tumor molecular phenotype. The miRNA-mRNA regulatory networks identified in BC are ripe for exploitation as biomarkers or targeted therapeutic strategies.

Highlights

  • Bladder cancer (BC) is a common urothelial malignancy, characterized by a high recurrence rate

  • Genes are acted upon by miRNAs where altering their expression acts on a variety of functions that impact cancer development and prognosis

  • More specific examples can be found with the epithelial transition to mesenchymal state (EMT) related miRNAs that have an important role in the molecular mechanisms, underlying key processes related to tumorigenesis, invasion and metastasis

Read more

Summary

Introduction

Bladder cancer (BC) is a common urothelial malignancy, characterized by a high recurrence rate. The biology of bladder cancer is complex and needs to be deciphered. The latest evidence reveals the critical role of the non-coding RNAs, microRNAs (miRNAs), as vital regulatory elements in cancer. The prognosis of BC is unfavorable, with a high percentage of disease recurrence regardless of treatment; these treatments include surgery, chemotherapy or, a combination of these two [1]. BC is a multifactorial disease where both exogenous and endogenous factors are eessential in early carcinogenesis, disease progression and responsible for the high recurrence rate, correlating to a specific mutation pattern [7]. New biomarkers for early diagnosis of bladder cancer, prognostic markers for its recurrence and predictive markers for response/overall survival are needed with great urgency [8]. Molecular markers can provide vital information to refine the optimal treatment, which in turn permits a good patient prognosis [5]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call